An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency

We demonstrated the short-term efficacy and safety of Growth hormone treatment in 64 Japanese adult GHD patients in a placebo-controlled, doubleblind study

Kazuo Chihara; Ekaterina Koledova; Akira Shimatsu; Yuzuru Kato; Hitoshi Kohno; Toshiaki Tanaka; Akira Teramoto; Peter C Bates; Andrea F Attanasio


Scholarcy highlights

  • Growth hormone is essential for growth in childhood but is necessary in adults for normal metabolic regulation
  • insulin-like growth factor-I and IGF-binding protein 3 concentrations were below normal in the PL/GH group; in contrast, the IGF-I and IGFBP-3 concentrations and SDS values were improved in the GH/GH group at baseline of the open-label study following treatment in the double-blind study
  • The benefits of GH replacement for adult GHD patients are well established for Caucasian patients
  • A previous double-blind study indicated the benefits of GH treatment for adult Japanese GHD patients
  • In this open-label study a different approach, using an individualized dosing regimen based on IGF-I levels, was implemented to compare the effects on efficacy and safety
  • There was a wide range of doses even within these two groups; individualized treatment based on IGF-I levels indicates that optimal dosage may differ in patients with different baseline characteristics, supporting this approach to GH treatment
  • It is recommended that the dose-adjustment method of Growth hormone administration, based on insulin-like growth factor-I levels, is adopted for future treatment of adult Japanese GHD patients

Need more features? Save interactive summary cards to your Scholarcy Library.